ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,320.76
0.43%
Dow Jones
42,427.87
0.60%
Gold vs US Dollar
2,648.80
-0.89%
Brent Oil
71.83
1.24%
Bitcoin
66,014.16
1.28%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. C4 Therapeutics Inc (CCCC)

  7. C4 Therapeutics Inc (CCCC) News

C4 Therapeutics (CCCC)

C4 Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CCCC
DateTimeSourceHeadlineSymbolCompany
20/09/202421:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
17/09/202422:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
17/09/202422:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
17/09/202422:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
17/09/202422:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
17/09/202422:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
13/09/202415:00GlobeNewswire Inc.C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:CCCCC4 Therapeutics Inc
10/09/202412:00GlobeNewswire Inc.C4 Therapeutics Announces Delivery of Second Development Candidate to BiogenNASDAQ:CCCCC4 Therapeutics Inc
08/09/202423:05GlobeNewswire Inc.C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:CCCCC4 Therapeutics Inc
03/09/202421:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
03/09/202421:51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
03/09/202412:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CCCCC4 Therapeutics Inc
03/09/202412:00GlobeNewswire Inc.C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of DirectorsNASDAQ:CCCCC4 Therapeutics Inc
29/08/202412:00GlobeNewswire Inc.C4 Therapeutics to Participate in Upcoming September Investor ConferencesNASDAQ:CCCCC4 Therapeutics Inc
14/08/202412:00GlobeNewswire Inc.C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper PresentationNASDAQ:CCCCC4 Therapeutics Inc
01/08/202412:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CCCCC4 Therapeutics Inc
01/08/202412:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CCCCC4 Therapeutics Inc
01/08/202412:00GlobeNewswire Inc.C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
16/07/202421:01GlobeNewswire Inc.C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024NASDAQ:CCCCC4 Therapeutics Inc
08/07/202412:00GlobeNewswire Inc.C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation DayNASDAQ:CCCCC4 Therapeutics Inc
11/06/202421:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
11/06/202421:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CCCCC4 Therapeutics Inc
10/06/202412:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CCCCC4 Therapeutics Inc
10/06/202412:00GlobeNewswire Inc.C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of DirectorsNASDAQ:CCCCC4 Therapeutics Inc
08/05/202412:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CCCCC4 Therapeutics Inc
08/05/202412:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CCCCC4 Therapeutics Inc
08/05/202412:00GlobeNewswire Inc.C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CCCCC4 Therapeutics Inc
29/04/202421:01GlobeNewswire Inc.C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CCCCC4 Therapeutics Inc
09/04/202412:00GlobeNewswire Inc.C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology ForumNASDAQ:CCCCC4 Therapeutics Inc
08/04/202413:00GlobeNewswire Inc.C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024NASDAQ:CCCCC4 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CCCC

Your Recent History

NASDAQ
TOP
TOP Financial
NYSE
BRT
BRT Apartments
TG
6NF
Newlat Food
COIN
FDCCCUST
FIDANCE
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved